- Home
- PMM vs CVRX Comparison
PMM vs CVRX Comparison
Compare PMM & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- CVRX
- Stock Information
- Founded
- PMM 1989
- CVRX 2000
- Country
- PMM United States
- CVRX United States
- Employees
- PMM N/A
- CVRX N/A
- Industry
- PMM Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PMM Finance
- CVRX Health Care
- Exchange
- PMM Nasdaq
- CVRX Nasdaq
- Market Cap
- PMM 287.2M
- CVRX 311.3M
- IPO Year
- PMM N/A
- CVRX 2021
- Fundamental
- Price
- PMM $6.05
- CVRX $12.11
- Analyst Decision
- PMM
- CVRX Buy
- Analyst Count
- PMM 0
- CVRX 7
- Target Price
- PMM N/A
- CVRX $16.67
- AVG Volume (30 Days)
- PMM 118.3K
- CVRX 187.2K
- Earning Date
- PMM 01-01-0001
- CVRX 01-23-2025
- Dividend Yield
- PMM 4.68%
- CVRX N/A
- EPS Growth
- PMM N/A
- CVRX N/A
- EPS
- PMM 0.23
- CVRX N/A
- Revenue
- PMM N/A
- CVRX $47,255,000.00
- Revenue This Year
- PMM N/A
- CVRX $31.78
- Revenue Next Year
- PMM N/A
- CVRX $26.42
- P/E Ratio
- PMM $26.52
- CVRX N/A
- Revenue Growth
- PMM N/A
- CVRX 34.38
- 52 Week Low
- PMM $5.00
- CVRX $6.40
- 52 Week High
- PMM $6.42
- CVRX $33.14
- Technical
- Relative Strength Index (RSI)
- PMM 34.89
- CVRX 38.54
- Support Level
- PMM $6.04
- CVRX $12.57
- Resistance Level
- PMM $6.43
- CVRX $13.68
- Average True Range (ATR)
- PMM 0.08
- CVRX 0.85
- MACD
- PMM -0.03
- CVRX -0.35
- Stochastic Oscillator
- PMM 16.10
- CVRX 17.11
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.